$IDXX

Generating a unique summary for IDXX…

AI-generated for information only — not investment advice.

No company profile available for this ticker yet.

Institutions hold —% · insiders —%

No institutional filings available for this ticker.

No insider transactions reported.

Consensus score — (1 = strong buy, 5 = sell) · mean target —

No recent analyst actions.

Next report: not scheduled

No earnings history available.

No filings indexed for this ticker.

• IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

  WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).

  Mon, 31 Aug 2026 18:00:00 +0000

• Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?

  IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish outlook on its prospects.

  Wed, 26 Aug 2026 12:09:00 +0000

• Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?

  IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.

  Fri, 21 Aug 2026 13:54:00 +0000

• Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding

  Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]

  Thu, 20 Aug 2026 15:42:28 +0000

• Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?

  IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...

  Thu, 13 Aug 2026 02:10:11 +0000

• IDEXX (IDXX) Q2 2026 Earnings Call Transcript

  Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.

  Tue, 11 Aug 2026 16:28:15 +0000

• Here is Why Growth Investors Should Buy Idexx (IDXX) Now

  Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

  Thu, 06 Aug 2026 16:45:02 +0000

• IDEXX Laboratories Q2 Earnings Call Highlights

  IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s

  Tue, 04 Aug 2026 16:04:28 +0000